Clinical trial
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
NCT02637856 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 11, 2016
- Completion date
- May 3, 2019
- Enrollment
- 608 (actual)
- Sites
- 82
Conditions
As the registry lists them; a condition with its own page is linked.